论文部分内容阅读
目的探讨自拟消症抗癌方联合化疗治疗中晚期宫颈癌对患者血清白细胞介素-17(IL-17)、癌胚抗原(CEA)及人鳞状细胞癌抗原(SCC-Ag)水平的影响。方法将206例中晚期宫颈癌患者随机分为采取自拟消症抗癌方联合化疗治疗的研究组和采用化疗治疗的对照组各103例。检测并比较2组患者治疗前后血清IL-17、CEA及SCC-Ag水平。结果治疗前2组血清IL-17、CEA及SCC-Ag水平差异无统计学意义(P>0.05);治疗后2组血清IL-17、CEA及SCC-Ag水平较治疗前显著性降低,且研究组低于对照组,差异有统计学意义(P<0.05)。结论自拟消症抗癌方联合化疗治疗中晚期宫颈癌能显著降低患者血清IL-17、CEA及SCC-Ag水平。
Objective To investigate the effect of self-designed anti-cancer and chemotherapy combined with chemotherapy on the serum levels of interleukin-17, carcinoembryonic antigen (CEA) and human squamous cell carcinoma antigen (SCC-Ag) in patients with advanced cervical cancer influences. Methods 206 patients with advanced cervical cancer were randomly divided into study group taking self-destructive anti-cancer chemotherapy combined with chemotherapy group and control group with chemotherapy of 103 cases. The levels of serum IL-17, CEA and SCC-Ag in two groups before and after treatment were detected and compared. Results There was no significant difference in the levels of serum IL-17, CEA and SCC-Ag between the two groups before treatment (P> 0.05). Serum levels of IL-17, CEA and SCC-Ag in the two groups after treatment were significantly lower than those before treatment The study group was lower than the control group, the difference was statistically significant (P <0.05). Conclusions Self-destructive anti-cancer combined with chemotherapy for advanced cervical cancer can significantly reduce the serum IL-17, CEA and SCC-Ag levels.